Chordate Medical has secured trademark registration for Ozilia® in Japan. The company has previously registered the trademark in the EU, China, and the United Kingdom. Active applications are currently ongoing in the United States and Brazil.
“Securing global trademark protection is valuable and important for creating long-term opportunities, even though Japan is not currently one of our focus markets. Having registered trademarks in key markets makes the business more attractive to potential buyers,” says Anders Weilandt, CEO of Chordate Medical.
Ozilia was introduced in September 2023, replacing K.O.S as the brand name across all markets where Chordate operates. The rebranding aimed to simplify and harmonize the company’s global market presence while enhancing awareness of its technology and treatments.
The registration in Japan is part of Chordate Medical’s ongoing efforts to safeguard intellectual property rights in strategic markets worldwide.
Chordate’s exit strategy involves demonstrating clear market penetration in selected markets. The company’s value is built on three pillars: robust scientific evidence from clinical studies, demonstrable sales success in several selected markets, and a comprehensive portfolio of intellectual property assets such as patents and trademarks. Since October 2024, Chordate has engaged Partner International Switzerland GmbH as an advisor to identify an international buyer for the business.
